Error message

An illegal choice has been detected. Please contact the site administrator.

Omnes Capital's investments

Sector 
SaaS / Cloud
Entry Date 
2012
Business 
Venture Capital

Progexia

An alternative operator serving private health insurance companies

Progexia is an alternative operator serving private health insurance companies, wich provide solutions in the Cloud for reduce benefits payments costs.

Sector 
Medical devices
Entry Date 
2011
Business 
Venture Capital

Pixium

Up-and-coming leader in bionic vision and vision restoration systems (VRS)

Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.

“Within ten years, we can become the world leader in the market.”
BERNARD
GILLY
Executive Chairman
of Pixium Vision
Pixium Vision

A long-term view

In June 2014, Omnes Capital supported the initial public offering made by Pixium Vision, a start-up specialising in vision restoration systems (VRSs). The IPO was highly successful, as one would expect for a company at the leading edge of research into visual impairment. A month later, Bernard Gilly, head of Pixium Vision, confirmed its success, with a total of €39.5 million ultimately raised.
BERNARD GILLY
Executive Chairman of Pixium Vision

Disruptive innovation

Alexia Perouse (Partner at Omnes Capital) and Bernard Gilly first discussed vision restoration systems in the early 2000s. "VRSs aim to enable blind people to perceive shapes and movements, a really tremendous project. But their design came up against two hurdles, systems miniaturisation and real-time image transmission", explains Bernard Gilly. 

 

Pixium overcame these hurdles in 2011 when it launched IRIS (short for Intelligent Retinal Implant System), consisting of a pair of glasses with an integrated mini-camera linked to a pocket computer and a retinal implant that stimulates the brain cells. 

 

"It met all our criteria for investment: disruptive technology, a seasoned management team and a promising medtech sector", says Alexia Perouse. So in 2012, Omnes Capital invested €5 million.

BERNARD
GILLY
Executive Chairman
of Pixium Vision
What sets Pixium apart from its competitors?
Our technology. We are pioneers in VRSs working as artificial retinas. IRIS, our first implant, has between 50 and 150 electrodes and can be implanted under general anaesthetic in two hours. PRIMA, the next generation, will have more than one thousand wireless electrodes and will be implanted under local anaesthetic in just 30 minutes. Both are being developed by an international network of research scientists from the Vision Institute, Université Pierre-et- Marie-Curie and the universities of Stanford and Jerusalem.
What do you expect from your partnership with Omnes Capital?
Omnes Capital has always been a partner that assesses our decisions, our strategy and our new hires, such as Pierre Kemula (former head of Investor Relations at Ipsen) who joined us as CFO last June. Alexia Perouse and her team know our project intimately, as they do the biotechnology and medical devices markets in general. We are united by strong mutual trust, which also stems from our long-standing relationship with Alexia, whom I have known since 2000.
What are your ambitions for the next few years?
The market is structuring itself. Within ten years, we can become a world leader with IRIS and PRIMA, but also with our R&D work on optical nerve pathologies, such as glaucoma. Will this growth be achieved alone or as part of a major group following a buyout? Only time will tell.

Timeline

• 2011: Bernard Gilly founds Pixium Vision with a group of scientists working at the Vision Institute and Université Pierre-et-Marie-Curie
• 2012: The first funding round organised with Omnes Capital raises €23.5 million
• 2013: Clinical trials begin on IRIS
• 2014: The IPO raises €39.5 million
• 2015: Development of IRIS begins in the United-States
pixium-vision
Sector 
SaaS / Cloud
Entry Date 
2011
Business 
Venture Capital

viavoo

Software suite in SaaS mode providing semantic analysis of interactions

A SaaS developer, viavoo can provide real-time analysis of consumer feedback to gain insight into their online or point-of-sale shopping experience, their views about products and services or about after-sales service, etc.
Operating across multiple channels (email, chat, satisfaction surveys, blogs, forums, opinions, social media), the linguistic technology developed by viavoo provides results very close to human understanding and can identify situations, questions, opinions, suggestions, intentions and complaints in customer feedback.
The data collected by viavoo is intended to provide marketing and customer relationship insights that help to use the customer’s own voice to improve customer experience, differentiation, loyalty and retention.

 

Sector 
Retail & Distribution
Entry Date 
2011
Business 
Mezzanine Buyout & Growth Capital

Daltys

Hot and cold drink, sweet and sandwich vending machines for businesses

Daltys markets and operates hot and cold drink, sweet and sandwich vending machines for businesses, the healthcare and the hotel & catering sectors. Daltys’ installed base of 55,000 vending machines makes it the leading operator in France, with over 18,000 customers. The company also develops coffee-shop and multi-service concepts for public spaces.
In June 2011, Mezzanis arranged the mezzanine debt put in place in connection with the buyout of Daltys by its CEO Christophe Brancato plus 21 Centrale Partners and finadvance.

 

Sector 
SaaS / Cloud
Entry Date 
2011
Business 
Venture Capital

Trusted Shops

European leader in subscription-based certification of online retailers

Founded in 1999 and headquartered in Germany, the company audits online stores applying a set of over 100 criteria, such as solvency, price transparency, customer service and personal data protection. After a successful audit, Trusted Shops issues the Trust Badge seal of approval and provides the option of a guarantee for shoppers. Today, more than 20,000 ecommerce sites across Europe display the seal of approval and over 10 million purchases have been protected by the money-back guarantee.

Sector 
Hardware
Entry Date 
2010
Business 
Venture Capital

SOMOS SEMICONDUCTOR

Fabless semiconductor company

SOMOS is a fabless semiconductor company offering leading edge RF Power Amplifier, RF Front End, and RF Switch products and designs for 4G & 5G IoT and Smartphone applications. We leverage our unique IP and know-how to implement and deliver CMOS Power Amplifiers with unprecedented performance, Switches with extremely low harmonics, and RF Front Ends in smallest form factors in the industry. We deliver state-of-the art components to our customers, we make IP available for licensing, and offer custom design services.

Sector 
SaaS / Cloud
Entry Date 
2010
Business 
Venture Capital

Scality

Highly effective open infrastructure solution for large-scale unstructured data storage

Scality has developed RING distributed storage software, which provides a massively scalable solution for handling very large data volumes. RING is a patented and tested solution that has been deployed right around the world.

Sector 
Pharma
Entry Date 
2010
Business 
Venture Capital

Poxel

Innovative therapeutic solutions for type II diabetes patients

Poxel is a fast-growing biopharmaceutical company that exclusively develops novel drugs treating metabolic conditions and type II diabetes in particular.
Headquartered in Lyon, Poxel was spun off from Merck Serono in 2009 and is a leading global player in the field of metabolic disorders. Its flagship product, Imeglimin, successfully conducted a Phase II(b).

 

Sector 
SaaS / Cloud
Entry Date 
2010
Business 
Venture Capital

Sigfox

First telecom operator dedicated to connected objects
Sigfox is the first and only company to provide global cellular connectivity for the Internet of Things, fully geared to low-throughput communications. Sigfox is reinventing connectivity by radically lowering the price and energy consumption of connected devices. Sigfox’s connectivity solution is based on an antenna and base station infrastructure that is completely independent of existing networks, such as the telecommunications network. Sigfox locations: Paris, Madrid and San Francisco.
Sector 
Web
Entry Date 
2009
Business 
Venture Capital

Blablacar

Ridesharing leader in Europe

BlaBlaCar is the leading French start-up in long-distance car-sharing across Europe, with 10 million members in 13 countries. Its site and mobile applications enable drivers with empty seats to search for passengers they can split the cost with on shared journeys. The up-and-coming Paris-based start-up now has over 180 employees in eight countries and has achieved dazzling global growth. Its car-sharing service is the most intuitive and sophisticated in the market, which gives it a decisive edge when it expands into new countries. Every month, BlaBlaCar helps two million people to save money by travelling together, while making journeys a more sociable experience and reducing environmental impact.

Pages

NewsRoom
No result found.